Humana (HUM) Q4 2025 earnings review
The Stars Cliff Has Arrived: 2026 Earnings Slashed by ~47%
Humana delivered a 'solid' FY25 with $17.14 Adjusted EPS, but the narrative has shifted entirely to the immediate earnings collapse in FY26. Due to the severe drop in Medicare Advantage Star Ratings (impacting bonus payments) and the failure of their lawsuit to block it, management guided FY26 Adjusted EPS to 'at least $9.00'—a near halving of profitability. While CenterWell continues to outperform and revenue grew 12% in Q4, the core Insurance segment is under siege from rising medical costs (Benefit Ratio up to 93.1%) and the massive revenue hole from lost quality bonuses.
🐂 Bull Case
The services segment is firing on all cylinders. CenterWell revenue grew 17% YoY in Q4 to $5.9B. Primary Care patients served increased nearly 15% YTD, proving the integrated care delivery model works even while the insurance side struggles.
Individual Medicare Advantage membership decline for FY25 was approximately 425,000, significantly better than the previous guidance of 'up to 500,000'. Retention is holding up better than feared despite benefit rationalization.
🐻 Bear Case
The drop from $17.14 EPS in FY25 to ~$9.00 in FY26 is not a cycle—it's a structural reset caused by the Stars rating disaster. Until ratings recover (earliest impact FY27/28), profitability is effectively capped.
The Insurance Segment Benefit Ratio climbed to 93.1% in Q4 (up from 92.1% a year ago). Combined with a 12% revenue increase, this suggests Humana is growing top-line volume but losing efficiency on medical spend.
⚖️ Verdict: 🔴🔴
Bearish. The company is fundamentally broken until the Stars rating issue is resolved, which is a multi-year process. FY26 guidance confirms the worst-case scenario: a 47% earnings haircut. Despite CenterWell's strength, the core insurance engine has stalled.
Key Themes
The Stars Rating Hangover
The massive decline in Star Ratings for the 2025 measurement year (affecting 2026 payments) has materialized in guidance. With the lawsuit challenging these ratings rejected by the court, Humana faces a definitive revenue headwind. The guidance for 'at least $9.00' EPS in FY26 explicitly cites this headwind net of mitigation efforts.
CenterWell Outperformance
CenterWell (Primary Care, Home Health, Pharmacy) remains the bright spot. Segment revenue jumped to $5.88B in Q4 vs $5.04B prior year. Primary Care patient count grew ~15% YoY to 447,100. This diversification is the only thing preventing a complete washout in financial performance.
Operational Cost & Impairments
Q4 included significant noise: $221M in impairment charges (related to indefinite-lived intangible assets and joint ventures) and $129M in 'value creation initiative' costs (severance/consulting). While Adjusted numbers exclude these, they signal internal distress and asset write-downs during a pivot period.
Value Creation & Cost Cutting
Management continues to tout 'value creation initiatives' aimed at realigning the cost structure. The Consolidated Operating Cost Ratio improved slightly on a full-year basis (11.5% FY25 vs 11.8% FY24 GAAP), but Q4 saw pressure. Achieving the $9.00 floor in FY26 likely relies heavily on these aggressive cost-outs.
Other KPIs
Loss widened significantly from ($575 million) in 24Q4. The segment is bleeding money in the fourth quarter due to seasonality and higher benefit ratios, but the depth of the loss is concerning given the revenue growth.
Cash flow has deteriorated significantly compared to prior years (FY24 was $2.96B, FY23 was $3.98B). FY26 guidance projects $2.4B - $2.9B, indicating no expected recovery in cash generation despite cost-cutting efforts.
Modest growth from 546,700 in 24Q3. While the individual business shrinks due to strategic exits, the Group business provides some stability, though at lower margins.
Guidance
Decelerating/Reversing. This is a massive drop from FY25's $17.14. It reflects the full impact of the Stars rating loss. The 'at least' language suggests this is a floor, but it resets the company's valuation baseline significantly lower.
Decelerating. Down from $9.84 in FY25. Note the narrow spread between GAAP and Adjusted guidance for 2026 suggests fewer planned 'one-time' exclusions compared to 2025's massive adjustments ($7.30/share difference).
Accelerating (from a low base). Management anticipates doubling the individual MA pretax margin (normalizing for Stars). However, 'normalizing for Stars' is a theoretical exercise; the actual cash impact of Stars prevents true margin recovery in the P&L.
Stable. Roughly in line with FY25 performance ($2.57B YTD Q3). Shows that despite the earnings accounting hit from Stars, the cash generation engine isn't completely breaking, but it isn't growing either.
Key Questions
Stars Mitigation Specifics
You guided for 'at least $9.00' EPS. Precisely how much of the gross Stars revenue impact have you successfully mitigated through operational cuts to arrive at this floor?
CenterWell Margins vs. Growth
CenterWell revenue is soaring, but margins are being pressured by V28 risk model phase-ins. When does the J-curve regarding new clinic openings flatten to allow segment margins to expand accretion?
Medical Cost Trend Assumptions
With the Benefit Ratio hitting 93% in Q4, what specific utilization trends (inpatient vs outpatient) are embedded in the FY26 guidance to prevent further deterioration?